Literature DB >> 17710353

Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.

M R Allen1, D B Burr.   

Abstract

UNLABELLED: We aimed to determine the effects of bisphosphonates on mechanical properties independent of changes in bone density. Our results show that at equivalent bone densities, vertebrae from beagles treated with bisphosphonate have equivalent bone strength and reduced bone energy absorption compared to those from untreated animals.
INTRODUCTION: Assessing the relationship between mechanical properties and bone density allows a biomechanical evaluation of bone quality, with differences at a given density indicative of altered quality. The purpose of this study was to evaluate the strength-density and energy absorption-density relationships in vertebral bone following a one-year treatment with clinical doses of two different bisphosphonates in beagle dogs.
METHODS: Areal bone mineral density (aBMD) and compressive mechanical properties (ultimate load and energy absorption) were assessed on lumbar vertebrae from skeletally mature beagle dogs treated with vehicle (VEH), alendronate (ALN), or risedronate (RIS). Relationships among properties were assessed using analyses of covariance.
RESULTS: Neither treatment altered the strength-density relationship compared to VEH, suggesting increases in vertebral strength with bisphosphonate-treatment are explained by increased density. The energy absorption-density relationship was altered by ALN, resulting in significantly lower energy absorption capacity at a given aBMD compared to both VEH (-22%) and RIS (-14%).
CONCLUSIONS: These data document that after adjusting for increased aBMD, vertebrae from animals treated with bisphosphonates have similar strength as those from untreated animals. Conversely, when adjusted for increased aBMD, alendronate treatment, but not risedronate treatment, significantly reduces the energy required for vertebral fracture, indicative of an alteration in bone quality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710353     DOI: 10.1007/s00198-007-0451-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  20 in total

Review 1.  Bone strength: what are we trying to measure?

Authors:  J D Currey
Journal:  Calcif Tissue Int       Date:  2001-04-11       Impact factor: 4.333

2.  Tensile yield in compact bone is determined by strain, post-yield behaviour by mineral content.

Authors:  John D Currey
Journal:  J Biomech       Date:  2004-04       Impact factor: 2.712

3.  A biomechanical analysis of the effects of resorption cavities on cancellous bone strength.

Authors:  Christopher J Hernandez; Atul Gupta; Tony M Keaveny
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

4.  Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.

Authors:  Ruth Zoehrer; Paul Roschger; Eleftherios P Paschalis; Jochen G Hofstaetter; Erich Durchschlag; Peter Fratzl; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-07       Impact factor: 6.741

Review 5.  Basic biomechanical measurements of bone: a tutorial.

Authors:  C H Turner; D B Burr
Journal:  Bone       Date:  1993 Jul-Aug       Impact factor: 4.398

6.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

Authors:  S T Harris; N B Watts; H K Genant; C D McKeever; T Hangartner; M Keller; C H Chesnut; J Brown; E F Eriksen; M S Hoseyni; D W Axelrod; P D Miller
Journal:  JAMA       Date:  1999-10-13       Impact factor: 56.272

7.  Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.

Authors:  G Y Boivin; P M Chavassieux; A C Santora; J Yates; P J Meunier
Journal:  Bone       Date:  2000-11       Impact factor: 4.398

8.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy.

Authors:  Pierre D Delmas; Ego Seeman
Journal:  Bone       Date:  2004-04       Impact factor: 4.398

10.  Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses.

Authors:  P D Delmas; Zhengqing Li; Cyrus Cooper
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

View more
  18 in total

1.  Atraumatic segmental atypical femur fracture secondary to bisphosphonate use: A case report.

Authors:  Andrew J Lovy; Diana Patterson; Laura Skeeles; Richard Ghillani; David Joseph; Yangguan Wu; Rohit Hasija
Journal:  J Clin Orthop Trauma       Date:  2017-03-19

2.  Changes of elastic constants and anisotropy patterns in trabecular bone during disuse-induced bone loss assessed by poroelastic ultrasound.

Authors:  Luis Cardoso; Mitchell B Schaffler
Journal:  J Biomech Eng       Date:  2015-01       Impact factor: 2.097

Review 3.  Bone microdamage: a clinical perspective.

Authors:  R D Chapurlat; P D Delmas
Journal:  Osteoporos Int       Date:  2009-03-17       Impact factor: 4.507

4.  Density and architecture have greater effects on the toughness of trabecular bone than damage.

Authors:  Jacqueline G Garrison; Constance L Slaboch; Glen L Niebur
Journal:  Bone       Date:  2009-01-14       Impact factor: 4.398

5.  Short-term effect of zoledronic acid upon fracture resistance of the mandibular condyle and femoral head in an animal model.

Authors:  Fabio Camacho-Alonso; Pía López-Jornet; Ascensión Vicente-Hernández
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-05-01

6.  Effects of suppression of bone turnover on cortical and trabecular load sharing in the canine vertebral body.

Authors:  Senthil K Eswaran; Grant Bevill; Prem Nagarathnam; Matthew R Allen; David B Burr; Tony M Keaveny
Journal:  J Biomech       Date:  2009-01-31       Impact factor: 2.712

7.  Mandibular necrosis in beagle dogs treated with bisphosphonates.

Authors:  D B Burr; M R Allen
Journal:  Orthod Craniofac Res       Date:  2009-08       Impact factor: 1.826

8.  Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.

Authors:  David B Burr; Tamim Diab; Andrew Koivunemi; Mark Koivunemi; Matthew R Allen
Journal:  J Orthop Res       Date:  2009-10       Impact factor: 3.494

Review 9.  Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Authors:  R G G Russell; N B Watts; F H Ebetino; M J Rogers
Journal:  Osteoporos Int       Date:  2008-06       Impact factor: 4.507

10.  Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.

Authors:  Matthew R Allen; Susan Reinwald; David B Burr
Journal:  Calcif Tissue Int       Date:  2008-05-08       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.